ARIDIS PHARMACEUTICAL INC by Aridis Pharmaceuticals Inc. Analyst Price Targets - Benzinga

ARIDIS PHARMACEUTICAL INC by Aridis Pharmaceuticals Inc.

ARDSOTCEM

Trade with Public

Trade with Public

$0.3101

At close: Jul 28, 5:00 PM EST

$0.00020

-0.31-99.94%

After Hours: Nov 10, 8:36 AM EST

Overview News Earnings ForecastPrice TargetsFinancials Sentiment Ownership Compare

ARIDIS PHARMACEUTICAL INC by Aridis Pharmaceuticals Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for ARIDIS PHARMACEUTICAL INC by Aridis Pharmaceuticals Inc. (ARDS).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$2Upside to Avg. PT+999900.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 6, 2023	HC Wainwright & Co.	Vernon Bernardino	Maintained	Buy	$2
Oct 20, 2023	HC Wainwright & Co.	Vernon Bernardino	PT Cut	Buy	$10→$2

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Aridis Pharmaceuticals, Maintains $2 Price Target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Aridis Pharmaceuticals (OTC:ARDS) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $2

HC Wainwright & Co. analyst Vernon Bernardino maintains Aridis Pharmaceuticals (OTC:ARDS) with a Buy and lowers the price target from $10 to $2.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $10

HC Wainwright & Co. analyst Vernon Bernardino maintains Aridis Pharmaceuticals (NASDAQ:ARDS) with a Buy and lowers the price target from $19 to $10.

Benzinga Newsdesk

PRO
Maxim Group Downgrades Aridis Pharmaceuticals to Hold

Maxim Group analyst Jason McCarthy downgrades Aridis Pharmaceuticals (NASDAQ:ARDS) from Buy to Hold.

Benzinga Newsdesk

HC Wainwright Reiterates Buy And $19 Price Target On Aridis Pharmaceuticals

Bill Haddad

PRO
Watching Aridis Pharmaceuticals; Maxim Reiterates $13 Price Target, Buy Rating

Benzinga Newsdesk